

ADA Antibody (C-term)

Mouse Monoclonal Antibody (Mab) Catalog # AM2128b

Product Information

Application WB, E **Primary Accession** P00813 **Other Accession** NP 000013.2 Reactivity Human Host Mouse Clonality Monoclonal Isotype IgG1 **Clone Names** 608CT2.1.3 **Calculated MW** 40764 287-314 **Antigen Region**

Additional Information

Gene ID 100

Other Names Adenosine deaminase, Adenosine aminohydrolase, ADA, ADA1

Target/SpecificityThis ADA antibody is generated from mice immunized with a KLH conjugated

synthetic peptide between 287-314 amino acids from the C-terminal region of

human ADA.

Dilution WB~~1:500~1000 E~~Use at an assay dependent concentration.

Format Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide.

This antibody is purified through a protein G column, followed by dialysis

against PBS.

Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions ADA Antibody (C-term) is for research use only and not for use in diagnostic

or therapeutic procedures.

Protein Information

Name ADA

Synonyms ADA1

Function Catalyzes the hydrolytic deamination of adenosine and 2- deoxyadenosine

(PubMed: 16670267, PubMed: 23193172, PubMed: 26166670,

PubMed:8452534, PubMed:9361033). Plays an important role in purine metabolism and in adenosine homeostasis. Modulates signaling by extracellular adenosine, and so contributes indirectly to cellular signaling events. Acts as a positive regulator of T-cell coactivation, by binding DPP4 (PubMed:20959412). Its interaction with DPP4 regulates lymphocyte-epithelial cell adhesion (PubMed:11772392). Enhances dendritic cell immunogenicity by affecting dendritic cell costimulatory molecule expression and cytokines and chemokines secretion (By similarity). Enhances CD4+ T-cell differentiation and proliferation (PubMed: 20959412). Acts as a positive modulator of adenosine receptors ADORA1 and ADORA2A, by enhancing their ligand affinity via conformational change (PubMed:23193172). Stimulates plasminogen activation (PubMed: 15016824). Plays a role in male fertility (PubMed:21919946, PubMed:26166670). Plays a protective role in early postimplantation embryonic development (By similarity). Also responsible for the deamination of cordycepin (3'-deoxyadenosine), a fungal natural product that shows antitumor, antibacterial, antifungal, antivirus, and immune regulation properties (PubMed; 26038697).

Cellular Location

Cell membrane; Peripheral membrane protein; Extracellular side. Cell junction. Cytoplasmic vesicle lumen {ECO:0000250|UniProtKB:P03958}. Cytoplasm. Lysosome. Note=Colocalized with DPP4 at the cell surface.

Tissue Location

Found in all tissues, occurs in large amounts in T- lymphocytes (PubMed:20959412). Expressed at the time of weaning in gastrointestinal tissues.


Background

This gene encodes an enzyme that catalyzes the hydrolysis of adenosine to inosine. Various mutations have been described for this gene and have been linked to human diseases. Deficiency in this enzyme causes a form of severe combined immunodeficiency disease (SCID), in which there is dysfunction of both B and T lymphocytes with impaired cellular immunity and decreased production of immunoglobulins, whereas elevated levels of this enzyme have been associated with congenital hemolytic anemia.

References

Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Gloria-Bottini, F., et al. Am. J. Med. Sci. 340(2):103-108(2010) Levine, A.J., et al. Cancer Epidemiol. Biomarkers Prev. 19(7):1812-1821(2010) Spina, C., et al. Cancer Invest. (2010) In press: Ri, G., et al. Anticancer Res. 30(6):2347-2349(2010)

Images



All lanes: Anti- ADA Antibody (C-term) at 1:1000 dilution + CCRF-CEM whole cell lysate Lysates/proteins at 20 µg per lane. Secondary: Goat Anti-Mouse IgG, (H+L), Peroxidase conjugated (ASP1613) at 1/8000 dilution. Observed band size: 41 KDa Blocking/Dilution buffer: 5% NFDM/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.